Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FM19G11 is an inhibitor of hypoxia inducible factor (HIF) α-subunit (IC50 = 80 nM in hypoxia induced luciferase assay).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 10,000 | |||
5 mg | 在庫あり | ¥ 22,500 | |||
10 mg | 在庫あり | ¥ 41,000 | |||
25 mg | 在庫あり | ¥ 91,500 | |||
50 mg | 在庫あり | ¥ 135,500 | |||
100 mg | 在庫あり | ¥ 193,500 | |||
500 mg | 在庫あり | ¥ 397,000 |
説明 | FM19G11 is an inhibitor of hypoxia inducible factor (HIF) α-subunit (IC50 = 80 nM in hypoxia induced luciferase assay). |
In vitro | FM19G11 (500 nM) promotes oligodendrocyte differentiation under hypoxic conditions[1]. FM19G11 (300 nM) significantly enhances the pro-apoptotic effect of temozolomide, whereas FM19G11 does not induce apoptosis. In hypoxic GBM-XD, hypoxic T98G, and normoxic T98G cells, FM19G11 (300 nM) significantly inhibited the mRNA level of O6-methylguanine DNA-methyltransferase via the HIF-1α pathway[3]. |
In vivo | Intramedullary injection of FM19G11 improves locomotion in severe spinal cord injury and induces the expression of GAP43 and RIP at the injury[2]. |
別名 | FM19G11, HIF-1alpha/2alpha Inhibitor |
分子量 | 463.4 |
分子式 | C23H17N3O8 |
CAS No. | 329932-55-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (194.2 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FM19G11 329932-55-0 Angiogenesis Chromatin/Epigenetic HIF HIF-1alpha/2alpha Inhibitor HIF-1a/2a Inhibitor HIF-1α/2α Inhibitor Inhibitor inhibitor inhibit